A small number of recent reports have documented coexisting cerebral pathologic entities in patients with Rasmussen’s encephalitis. We report the case of a 4-year-old boy who presented with refractory seizures and was found to have both a ganglioglioma and Rasmussen’s encephalitis of the same hemisphere. The patient ultimately underwent a functional hemispherectomy with excellent seizure control. We also review the clinical and pathologic hallmarks of both gangliogliomas and Rasmussen’s encephalitis. We hope that the addition of this patient to the small but growing literature on dual pathology in Rasmussen’s encephalitis may help shed some light on the etiology of this mysterious disease.

Keywords:
Ganglioglioma, Hemispherectomy, Rasmussen’s encephalitis, Seizures
1.
Hart YM, Andermann F, Robitaille Y, Laxer KD, Rasmussen T, Davis R: Double pathology in Rasmussen’s syndrome. A window on the etiology? Neurology 1998;50:731–735.
2.
Yacubian EMT, Rosemberg S, Marie SKN, Valerio RMF, Jorge CL, Cukiert A: Double pathology in Rasmussen’s encephalitis: Etiologic considerations. Epilepsia 1996;37:495–500.
3.
Miller DC, Lang FF, Epstein FJ: Central nervous system gangliogliomas. Part 1: Pathology. J Neurosurg 1993;79:859–866.
4.
Wolf HK, Muller MB, Spanle M, Zentner J, Schramm J, Wiestler OD: Ganglioglioma: A detailed histopathological and immunohistochemical analysis of 61 cases. Acta Neuropathol 1994;88:166–173.
5.
Zentner J, Wolf HK, Ostertun B, Hufnagel A, Campos MG, Solymosi L, Schramm J: Gangliogliomas: Clinical, radiological, and histopathological findings in 51 patients. J Neurol Neurosurg Psychiatry 1994;57:1497–1502.
6.
Lang FF, Epstein FJ, Ransohoff J, Allen JC, Wisoff J, Abbott IR, Miller DC: Central nervous system gangliogliomas. Part 2: Clinical outcome. J Neurosurg 1993;79:867–873.
7.
Andrews JM, Thompson JA, Pysher TJ, Walker ML, Hammond ME: Chronic encephalitis, epilepsy, and cerebrovascular immune complex deposits. Ann Neurol 1990;28:88–90.
8.
Atkins MR, Terrell W, Hulette CM: Rasmussen’s syndrome: A study of potential viral etiology. Clin Neuropathol 1995;14:7–12.
9.
Farrell MA, Cheng L, Cornford ME, Grody WW, Vinters HV: Cytomegalovirus and Rasmussen’s encephalitis. Lancet 1991;337:1551–1552.
10.
Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, Hughes TE, Heinemann SF, McNamara JO: Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis. Science 1994;265:648–651.
11.
McLachlan RS, Girvin JP, Blume WT, Reichman H: Rasmussen’s chronic encephalitis in adults. Arch Neurol 1993;50:269–274.
12.
Hart YM, Cortez M, Andermann F, Hwang P, Fish DR, Dulac O, Silver K, Fejerman N, Cross H, Sherwin A, Caraballo R: Medical treatment of Rasmussen’s syndrome (chronic encephalitis and epilepsy): Effect of high-dose steroids or immunoglobulins in 19 patients. Neurology 1994;44:1030–1036.
13.
McLachlan RS, Levin S, Blume WT: Treatment of Rasmussen’s syndrome with ganciclovir. Neurology 1996;47:925–928.
14.
Peacock WJ: Hemispherectomy for the treatment of intractable seizures in childhood; in Adelson PD, Black PML (eds): Neurosurgery Clinics of North America. Philadelphia, Saunders, 1995, pp 549–564.
15.
Villemure JG, Andermann F, Rasmussen TB: Hemispherectomy for the treatment of epilepsy due to chronic encephalitis; in Andermann F (ed): Chronic Encephalitis and Epilepsy. Rasmussen’s Syndrome. Boston, Butterworth-Heinemann, 1991, pp 235–241.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.